American Century Companies Inc. Acquires 65,916 Shares of Hologic, Inc. $HOLX

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

American Century Companies Inc. increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 5.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,339,983 shares of the medical equipment provider's stock after acquiring an additional 65,916 shares during the period. American Century Companies Inc. owned about 0.60% of Hologic worth $82,771,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in HOLX. Victory Capital Management Inc. raised its holdings in shares of Hologic by 34.4% during the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock worth $408,283,000 after acquiring an additional 1,692,177 shares during the period. Nuance Investments LLC raised its holdings in shares of Hologic by 623.7% during the first quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider's stock worth $66,794,000 after acquiring an additional 931,920 shares during the period. Redwood Wealth Management Group LLC acquired a new stake in shares of Hologic during the first quarter worth $3,534,000. Invesco Ltd. increased its stake in Hologic by 18.8% in the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock valued at $298,655,000 after buying an additional 764,573 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Hologic by 26.9% in the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after buying an additional 668,086 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Performance

Shares of HOLX stock traded up $0.94 during midday trading on Wednesday, hitting $68.76. 1,890,938 shares of the company were exchanged, compared to its average volume of 1,834,424. The firm has a market capitalization of $15.29 billion, a P/E ratio of 28.53, a PEG ratio of 2.46 and a beta of 0.49. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The firm's 50 day moving average price is $65.79 and its two-hundred day moving average price is $62.55. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. Hologic's revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on HOLX shares. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Stephens lowered their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and lifted their price target for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. UBS Group lifted their price target on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research note on Thursday, July 31st. Finally, Mizuho set a $75.00 price target on shares of Hologic in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.